Publications Anton Martens

Key publications (for the complete list click here)

Gutierrez A, Pan L, Groen RW, Baleydier F, Kentsis A, Marineau J, Grebliunaite R, Kozakewich E, Reed C, Pflumio F, Poglio S, Uzan B, Clemons P, Verplank L, An F, Burbank J, Norton S, Tolliday N, Steen H, Weng AP, Yuan H, Bradner JE, Mitsiades C, Look AT, Aster JC (2014), Phenothiazines induce PP2A-mediated apoptosis in T cell acute lymphoblastic leukemia, J Clin Invest, 124, 644-55.

de Haart SJ, van de Donk NW, Minnema MC, Huang JH, Aarts-Riemens T, Bovenschen N, Yuan H, Groen RW, McMillin DW, Jakubikova J, Lokhorst HM, Martens AC, Mitsiades CS, Mutis T (2013), Accessory cells of the microenvironment protect multiple myeloma from T-cell cytotoxicity through cell adhesion-mediated immune resistance, Clin Cancer Res, 19, 5591-601.

Groen, R. W. J., Noort, W. A., Raymakers, R. A., Prins, H.-J., Aalders, L., Hofhuis, F. M., Moerer, P., van Velzen JF, Bloem A, van Kessel B, Rozemuller H, van Binsbergen E. Buijs A, Yuan H, de bruijn JD, de Weers M, Parren WHI, Schuringa JJ, Lokhorst H, Mutis T and Martens AC (2012), Reconstructing the human hematopoietic niche in immunodeficient mice: opportunities for studying primary multiple myeloma, Blood, 120, e9–e16

Groen RWJ, Reijmers RM, de Rooij MRF, Kocemba KA, de Haan-Kramer A, Overdijk MB, Kersten MJ, Rozemuller H, Martens AC, Bergsagel PL, ST Pals, Spaargaren M (2011), N-cadherin mediated adhesion of Multiple Myeloma cells inhibits osteoblast differentiation, Haematologica, 96, 1653-1661.

Marcu-Malina V, Heijhuurs S, van Buuren M, Hartkamp L, Strand S, Sebestyen Z, Scholten K, Martens AC, Kuball J (2011), Redirecting αβT cells against cancer cells by transfer of a broadly tumor-reactive γδT-cell receptor. Blood, 118, 50-59.

Vercoulen Y, Guichelaar T, Meerding J, Emmelot M, Pingen M, Storm G, Coffer P, Sawitzki B, Martens ACM, Mutis T, Prakken B (2011), Application of cultured human regulatory T cells requires preclinical in vivo evaluation, Journal Allergy Clin Immunol, in press.

Roodhart JML, Daenen LGM, Stigter ECA, Prins HJ, Schipper HS, Backer MJG, van Amersfoort M, Vermaat JSP, Moerer P, Ishihara K, Kalkhoven E, Derksen PWB, Medema RH, Martens AC, Brenkman AB, Voest EE (2011), Mesenchymal Stem Cells induce resistance to chemotherapy via the release of polyunsaturated fatty acids, Cancer Cell, 20, 370-383.

Rozemuller H, Prins H-J, Naaijkens B, Staal J, Bühring H-J, Martens AC (2010), Prospective isolation of mesenchymal stem cells from multiple mammalian species using cross-reacting anti human monoclonal antibodies, Stem Cells Dev, 19, 1911-21.

Spaapen RM, Groen RWJ ,van den Oudenalder K, , Guichelaar T, van Elk M, Aarts T, Bloem AC, Storm G, Martens AC, Lokhorst HM, Mutis T (2010), Eradication of medullary multiple myeloma by CD4+ cytotoxic human T lymphocytes directed at a single minor histocompatibility antigen, Clin Cancer Res, 16, 5481-7.

Reijmers RM, Groen RJW, Rozemuller H, Kuil A, de Haan-Kramer A, Csikós T, Martens AC, Spaargaren M, Pals ST (2010), Targeting EXT-1 reveals a crucial role for heparan sulfate in the growth of multiple myeloma, Blood, 115, 601-604.

Prins HJ, Rozemuller H, Vonk-Griffioen S, Verweij VG, Dhert W, Slaper-Cortenbach I, Martens AC (2009), Bone forming capacity of mesenchymal stromal cells when cultured in the presence of human platelet lysate as Substitute for fetal bovine serum. Tissue Eng Part A, 15, 3741-51.

Rozemuller H, van der Spek E, Bogers-Boer LH, Zwart MC, Verweij V, Emmelot ME, Groen RW Spaapen R, Bloem AC, Lokhorst HM, Mutis T, Martens AC (2008), A bioluminescence imaging based in vivo model for preclinical testing of novel cellular immunotherapy strategies to improve graft versus myeloma, Hematologica, 93, 1049-57.

Olivo C, Alblas J, Verweij V, Van Zonneveld AJ, Dhert WJ, Martens AC (2008), In vivo bioluminescence imaging study to monitor ectopic bone formation by luciferase gene marked mesenchymal stem cells, J Orthop Res, 26, 901-9.

Rozemuller H, Knaän-Shanzer S, Hagenbeek A, van Bloois L, Storm G, Martens ACM (2004), Enhanced engraftment of human cells in RAG2/gc double knock out mice after treatment with CL2MDP-liposomes, Exp Hemat, 32, 1118-1125.

Kruyt MC, Stijns MMC, Fedorovich NE, de Bruijn JD, van Blitterswijk CA, Verbout AJ, Rozemuller H, Hagenbeek A, Dhert WJA, Martens ACM (2004), Genetic marking with the dLNGFR-gene for tacing goat cells in bone tissue engineering, J Orthopaedic Research, 22, 697-702.

van Rijn RS, Simonetti ER, Hagenbeek A, Hogenes MC, de Weger RA, Canninga-van Dijk MR, Weijer K, Spits H, Storm G, van Bloois L, Rijkers G, Martens AC, Ebeling SB (2003), A new xenograft model for graft-versus-host disease by intravenous transfer of human peripheral blood mononuclear cells in RAG2-/- gammac-/- double-mutant mice, Blood, 102, 2522-31.

Rombouts WJC, Martens ACM, Ploemacher RE (2000), Identification of variables determining the engraftment potential of human acute myeloid leukemia in the immunodeficient NOD/SCID human chimera model, Leukemia, 14, 889-97.

Rozemuller H, Rombouts WJC, Touw IP, FitzGerald DJP, Kreitman RJ, Hagenbeek A, Martens ACM (1998), In vivo targeting of leukemic cells using diphtheria toxin fused to murine GM-CSF, Leukemia, 12, 710-717.

Terpstra W, Rozemuller H, Breems DA, Rombouts WJC, Prins A, FitzGerald DJP, Kreitman RJ, Wielenga JJ, Ploemacher RE, Löwenberg B, Hagenbeek A, Martens ACM (1997), Diphtheria toxin fused to GM-CSF eliminates AML cells with the potential to initiate leukemia in immunodeficient mice, but spares normal hemopoietic stem cells, Blood, 90, 3735-3742.

Martens AC, Schultz F, Hagenbeek A (1987), Nonhomogeneous distribution of leukemia in the bone marrow during minimal residual disease, Blood, 70, 1073-1078.

TOP